Mirvetuximab soravtansine
- Generic Name
- Mirvetuximab soravtansine
- Brand Names
- Elahere
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1453084-37-1
- Unique Ingredient Identifier
- 98DE7VN88D
- Background
Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine). DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1.
...
- Indication
Mirvetuximab soravtansine is indicated for the treatment of adult patients with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Patients are selected for therapy based on an FDA-approved test.
...
- Associated Conditions
- Platinum-resistant Epithelial Ovarian Cancer, Platinum Resistant Primary Peritoneal Cancer, Platinum drug resistant Fallopian tube cancer
- Associated Therapies
- -
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 366
- Registration Number
- NCT02631876
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸Georgia Regents University (GRU)-Medical College of Georgia (MCG) - Cancer Center, Augusta, Georgia, United States
🇺🇸UCLA Women's Health Clinical Research Unit - OBGYN, Los Angeles, California, United States
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 264
- Registration Number
- NCT02606305
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇧🇪Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg - Leuvens Kankerinstituut, Leuven, Belgium
🇺🇸The Ohio State University, Hilliard, Ohio, United States
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors
- First Posted Date
- 2012-06-01
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 206
- Registration Number
- NCT01609556
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.